XML 59 R41.htm IDEA: XBRL DOCUMENT v3.25.4
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of assets acquired and liabilities assumed and allocation of consideration
The following table presents the fair value of the assets acquired and liabilities assumed in the acquisition of NGC as of the acquisition date and an allocation of the consideration to net assets acquired:
Cash$146 
Accounts receivable, net2,487 
Prepaid expenses and other current assets398 
Inventories, net3,400 
Property, plant and equipment, net10,858 
Right-of-use assets2,842 
Licenses15,387 
Trade name201 
Goodwill1,285 
Deferred tax liabilities(265)
Liabilities assumed(12,966)
Net assets acquired$23,773 
Consideration paid in cash, net of working capital adjustments$2,368 
Equity consideration(1)
15,053 
Contingent consideration classified as a liability(2)
6,352 
Total consideration$23,773 
Cash outflow, net of cash acquired$2,222 
(1) The fair value of the consideration, paid through the issuance of SVS, was based on a third-party valuation that took into account transfer restrictions and the time value of money.
(2) On April 11, 2025, the Company issued 621,166 SVS and paid $3.2 million in cash to settle this contingent consideration obligation.
The following table presents the fair value of the assets acquired and liabilities assumed in the acquisition of Curaleaf Poland as of the acquisition date and an allocation of the consideration to net assets acquired:
Cash$48 
Accounts receivable, net414 
Prepaid expenses and other current assets2 
Inventories, net661 
Property, plant and equipment, net14 
Licenses2,063 
Trade name97 
Non-compete agreements32 
Goodwill931 
Deferred tax liabilities(548)
Liabilities assumed(891)
Net assets acquired$2,823 
Consideration paid in cash, net of working capital adjustments$832 
Equity consideration(1)
773 
Deferred consideration classified as a liability(2)
1,218 
Total consideration$2,823 
Cash outflow, net of cash acquired$784 
(1) The fair value of the consideration paid through the issuance of SVS was based on a third-party valuation that took into account the time value of money.
(2) On April 14, 2025, the Company issued 96,052 SVS and paid $0.4 million in cash to settle this deferred consideration obligation.
The Company accounted for its acquisition of Dark Heart as an asset acquisition.
The following table presents the fair value of the assets acquired in the acquisition of Dark Heart as of the acquisition date and an allocation of the consideration to net assets acquired:
Intellectual Property$9,365 
Net assets acquired$9,365 
Consideration paid in cash, net of working capital adjustments$1,693 
Cancelled loan (including accrued interest)7,672 
Total consideration$9,365 
Schedule of changes in the contingent consideration account balance
The changes in the Company’s contingent consideration liability as of December 31, 2025 and 2024 were as follows:
EMMAC(1)
NGC(2)
Total
Total contingent consideration liability, December 31, 2023$4,724 $— $4,724 
Contingent consideration recognized on acquisition— 6,352 6,352 
Revaluation of contingent consideration(1,820)(3,042)(4,862)
Effect of exchange rate differences(67)— (67)
Total contingent consideration liability, December 31, 20242,837 3,310 6,147 
Cash payments of contingent consideration— (3,236)(3,236)
Issuance of SVS as settlement of contingent consideration— (497)(497)
Revaluation of contingent consideration306 335 641 
Effect of exchange rate differences215 — 215 
Gain on contingent consideration not paid— 88 88 
Total contingent consideration liability, December 31, 20253,358 — 3,358 
Less: Contingent consideration liability - current— — — 
'Contingent consideration liability - net of current$3,358 $— $3,358 
(1) Contingent on the ability of Curaleaf International Holdings Limited (“Curaleaf International”) to obtain a recreational cannabis license in Europe and is payable in both cash and SVS upon achievement. Payouts, if any, are expected in 2027.
(2) Contingent obligation was tied to NGC achieving certain margin targets during the fiscal year ending December 31, 2024.
Schedule of deferred consideration liability
The changes in the Company’s deferred consideration liability as of December 31, 2025 and 2024 were as follows:
Tryke(1)
NRPC(3)
Curaleaf Poland(4)
Other(5)
Total
Total deferred consideration liability, December 31, 2023$41,652 $2,000 $— $— $43,652 
Deferred consideration recognized on acquisition— — 1,218 — 1,218 
Interest expense on deferred consideration5,913 — — — 5,913 
Effect of exchange rate differences— — 82 — 82 
Reversal of interest expense on deferred consideration(11)— — — (11)
Change in fair value on deferred consideration paid— — (796)— (796)
Post-closing purchase price adjustment (2)

(3,740)— — — (3,740)
Cash payments of deferred consideration(11,250)— — — (11,250)
Total deferred consideration liability, December 31, 202432,564 2,000 504 — 35,068 
Deferred consideration recognized on acquisition— — — 920 920 
Interest expense on deferred consideration2,436 — — — 2,436 
Effect of exchange rate differences— — 17 46 63 
Change in fair value on deferred consideration paid— — (46)— (46)
Issuance of SVS as settlements of deferred consideration— — (77)— (77)
Cash payments of deferred consideration(35,000)— (398)— (35,398)
Total deferred consideration liability, December 31, 2025— 2,000 — 966 2,966 
Less: Deferred consideration liability - current— (2,000)— (966)(2,966)
Deferred consideration liability - net of current$— $— $— $— $— 
(1) Related to the second and third anniversary payment due from the Company to the sellers of Tryke of $21.2 million and $25.0 million, respectively, settled in October 2025.
(2) On October 4, 2024, the Company entered into a settlement agreement with the sellers of Tryke Companies, pursuant to which the Company received a $3.7 million post-closing purchase price adjustment that reduced the Company’s second anniversary payment.
(3) Represents amounts withheld in connection with the acquisition of Natural Remedy Patient Center LLC (“NRPC”) as security for indemnification obligations. In January 2026, upon receipt of a final, non-appealable order, the $2.0 million holdback became payable. The Company retained $1.2 million of this amount for potential tax exposure (scheduled for release in August 2026 and August 2027, subject to IRS claims) and deducted legal fees incurred during the litigation as permitted under the purchase agreement. The remaining amount, net of the tax holdback and legal fees, was paid in February 2026.
(4) Related to Curaleaf Poland’s achievement of certain earnings metrics during the fiscal year ending December 31, 2024. On April 14, 2025, the Company settled this obligation through a cash payment of $0.4 million and the issuance of 96,052 SVS.
(5) Incurred in connection with an individually immaterial acquisition consummated during the second quarter of 2025 within the Company's international operations.